Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment.
Bone mineral metabolism and mineralization before and during treatment were studied in 10 girls aged 6.9-8.4 years affected by central precocious puberty and treated with gonadotrophin-releasing hormone agonist (GnRHa) leuprolide acetate depot, in order to understand better the consequences of oestrogen deficiency and the reduction of growth hormone (GH)-insulin-like growth factor I (IGF-I) axis activity. Before and after 12 months of therapy, the patients underwent a clonidine stimulation test and a 4-day calcitriol osteoblast stimulation test. On day 0, day 5 and at 3-month intervals thereafter, serum calcium, phosphate, alkaline phosphatase, IGF-I, IGF binding protein 3 (IGFBP-3), GH, GH binding protein and osteocalcin levels were measured; urinary calcium, phosphate and hydroxyproline levels were evaluated in fasting spot samples. Trabecular and cortical bone mass variations, measured by dual X-ray absorptiometry in the lumbar spine and by dual photon absorptiometry in the radius, respectively were evaluated before the start and after 12 months of therapy. During treatment, a decrease of serum oestradiol levels from pubertal to prepubertal levels was observed. The GH peak following clonidine diminished significantly after 1 year. Growth hormone binding protein showed a slight increase, and IGF-I and IGFBP-3 decreased, although not significantly. Osteocalcin levels decreased significantly after 9 and 12 months of treatment, but they did not change significantly after calcitriol load, either before or after GnRHa therapy. Urinary hydroxyproline decreased significantly after 12 months.(ABSTRACT TRUNCATED AT 250 WORDS)
Antoniazzi
F
F
Clinica Pediatrica, Università di Verona, Italy.
Bertoldo
F
F
Zamboni
G
G
Valentini
R
R
Sirpresi
S
S
Cavallo
L
L
Adami
S
S
Tatò
L
L
D001827:Body Height; D015519:Bone Density; D001842:Bone and Bones / Q000378:metabolism*; D002113:Calcification, Physiologic; D002117:Calcitriol; D002648:Child; D003000:Clonidine; D003692:Delayed-Action Preparations; D005260:Female; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006909:Hydroxyproline / Q000652:urine; D007334:Insulin-Like Growth Factor I / Q000378:metabolism; D016729:Leuprolide / Q000627:therapeutic use*; D008903:Minerals / Q000378:metabolism*; D010006:Osteoblasts / Q000187:drug effects; D015675:Osteocalcin / Q000097:blood; D011629:Puberty, Precocious / Q000188:drug therapy / Q000378:metabolism*; D013565:Sympatholytics
D003692:Delayed-Action Preparations; D008903:Minerals; D013565:Sympatholytics; D015675:Osteocalcin; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D016729:Leuprolide; D002117:Calcitriol; D003000:Clonidine; D006909:Hydroxyproline